Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Eur J Med Chem ; 208: 112754, 2020 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-32883638

RESUMO

The biological effects of flavonoids on mammal cells are diverse, ranging from scavenging free radicals and anti-cancer activity to anti-influenza activity. Despite appreciable effort to understand the anti-influenza activity of flavonoids, there is no clear consensus about their precise mode-of-action at a cellular level. Here, we report the development and validation of a screening assay based on AlphaScreen technology and illustrate its application for determination of the inhibitory potency of a large set of polyols against PA N-terminal domain (PA-Nter) of influenza RNA-dependent RNA polymerase featuring endonuclease activity. The most potent inhibitors we identified were luteolin with an IC50 of 72 ± 2 nM and its 8-C-glucoside orientin with an IC50 of 43 ± 2 nM. Submicromolar inhibitors were also evaluated by an in vitro endonuclease activity assay using single-stranded DNA, and the results were in full agreement with data from the competitive AlphaScreen assay. Using X-ray crystallography, we analyzed structures of the PA-Nter in complex with luteolin at 2.0 Å resolution and quambalarine B at 2.5 Å resolution, which clearly revealed the binding pose of these polyols coordinated to two manganese ions in the endonuclease active site. Using two distinct assays along with the structural work, we have presumably identified and characterized the molecular mode-of-action of flavonoids in influenza-infected cells.


Assuntos
Antivirais/química , Endonucleases/antagonistas & inibidores , Inibidores Enzimáticos/química , Flavonoides/química , Vírus da Influenza A/enzimologia , Proteínas Virais/antagonistas & inibidores , Antivirais/metabolismo , Cristalografia por Raios X , Avaliação Pré-Clínica de Medicamentos , Endonucleases/química , Endonucleases/metabolismo , Ensaios Enzimáticos/métodos , Inibidores Enzimáticos/metabolismo , Flavonoides/metabolismo , Testes de Sensibilidade Microbiana , Estrutura Molecular , Ligação Proteica , Domínios Proteicos , RNA Polimerase Dependente de RNA/antagonistas & inibidores , RNA Polimerase Dependente de RNA/química , RNA Polimerase Dependente de RNA/metabolismo , Relação Estrutura-Atividade , Proteínas Virais/química , Proteínas Virais/metabolismo
2.
Biochem J ; 475(23): 3847-3860, 2018 12 10.
Artigo em Inglês | MEDLINE | ID: mdl-30404922

RESUMO

Influenza neuraminidase is responsible for the escape of new viral particles from the infected cell surface. Several neuraminidase inhibitors are used clinically to treat patients or stockpiled for emergencies. However, the increasing development of viral resistance against approved inhibitors has underscored the need for the development of new antivirals effective against resistant influenza strains. A facile, sensitive, and inexpensive screening method would help achieve this goal. Recently, we described a multiwell plate-based DNA-linked inhibitor antibody assay (DIANA). This highly sensitive method can quantify femtomolar concentrations of enzymes. DIANA also has been applied to high-throughput enzyme inhibitor screening, allowing the evaluation of inhibition constants from a single inhibitor concentration. Here, we report the design, synthesis, and structural characterization of a tamiphosphor derivative linked to a reporter DNA oligonucleotide for the development of a DIANA-type assay to screen potential influenza neuraminidase inhibitors. The neuraminidase is first captured by an immobilized antibody, and the test compound competes for binding to the enzyme with the oligo-linked detection probe, which is then quantified by qPCR. We validated this novel assay by comparing it with the standard fluorometric assay and demonstrated its usefulness for sensitive neuraminidase detection as well as high-throughput screening of potential new neuraminidase inhibitors.


Assuntos
DNA/química , Avaliação Pré-Clínica de Medicamentos/métodos , Inibidores Enzimáticos/farmacologia , Vírus da Influenza A/efeitos dos fármacos , Oseltamivir/análogos & derivados , Ácidos Fosforosos/química , Antivirais/química , Antivirais/farmacologia , Inibidores Enzimáticos/química , Humanos , Vírus da Influenza A/enzimologia , Vírus da Influenza A/fisiologia , Influenza Humana/tratamento farmacológico , Influenza Humana/enzimologia , Influenza Humana/virologia , Neuraminidase/antagonistas & inibidores , Neuraminidase/metabolismo , Oseltamivir/química , Reprodutibilidade dos Testes , Proteínas Virais/antagonistas & inibidores , Proteínas Virais/metabolismo
3.
J Med Chem ; 51(15): 4839-43, 2008 Aug 14.
Artigo em Inglês | MEDLINE | ID: mdl-18598016

RESUMO

HIV protease (PR) is a prime target for rational anti-HIV drug design. We have previously identified icosahedral metallacarboranes as a novel class of nonpeptidic protease inhibitors. Now we show that substituted metallacarboranes are potent and specific competitive inhibitors of drug-resistant HIV PRs prepared either by site-directed mutagenesis or cloned from HIV-positive patients. Molecular modeling explains the inhibition profile of metallacarboranes by their unconventional binding mode.


Assuntos
Compostos de Boro/química , Compostos de Boro/farmacologia , Farmacorresistência Viral/efeitos dos fármacos , Inibidores da Protease de HIV/química , Inibidores da Protease de HIV/farmacologia , Protease de HIV/metabolismo , Metais/química , Cristalografia por Raios X , Protease de HIV/química , Protease de HIV/genética , HIV-1/efeitos dos fármacos , HIV-1/enzimologia , Modelos Moleculares , Estrutura Molecular , Mutação/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA